-
公开(公告)号：EP2933252A1
公开(公告)日：2015-10-21
申请号：EP15151030.2
申请日：2010-07-12
IPC分类号： C07D401/12 , C07D401/14 , C07D407/14 , C07D413/14 , C07D471/04 , C07D491/048 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/506 , A61P9/00 , A61P25/28 , A61P29/00 , A61P37/00
CPC分类号： A61K31/444 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/585 , A61K45/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/048
摘要： The present invention relates to compounds of Formula (I): where in X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase ("ASK1") inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
摘要翻译： 本发明涉及式（I）化合物：其中X1，X2，X3，X4，X5，X6，X7，X8，R1，R2，R3如上定义。 该化合物具有凋亡信号调节激酶（“ASK1”）抑制活性，因此可用于治疗ASK1介导的病症，包括自身免疫性疾病，炎性疾病，心血管疾病和神经变性疾病。 本发明还涉及包含一种或多种式（I）化合物的药物组合物和制备式（I）化合物的方法。
-
公开(公告)号：EP2933252B1
公开(公告)日：2018-01-03
申请号：EP15151030.2
申请日：2010-07-12
IPC分类号： C07D401/12 , C07D401/14 , C07D407/14 , C07D413/14 , C07D471/04 , C07D491/048 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/506 , A61P9/00 , A61P25/28 , A61P29/00 , A61P37/00
CPC分类号： A61K31/444 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/585 , A61K45/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/048
摘要： The present invention relates to compounds of Formula (I): where in X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase ("ASK1") inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
-
公开(公告)号：EP3275870B1
公开(公告)日：2020-02-05
申请号：EP17187226.0
申请日：2012-05-08
发明人： Corkey, Britton Kenneth , Elzein, Elfatih , Jiang, Robert H , Kalla, Rao V , Kobayashi, Tetsuya , Koltun, Dmitry , Li, Xiaofen , Martinez, Ruben , Notte, Gregory , Parkhill, Eric Q , Perry, Thao , Zablocki, Jeff , Venkataramani, Chandrasekar , Graupe, Michael , Guerrero, Juan
IPC分类号： C07D237/32 , C07D253/08 , C07D265/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/12 , C07D403/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/14 , C07D217/24 , C07D239/88 , C07D239/90 , C07D405/12
-
公开(公告)号：EP3275870A1
公开(公告)日：2018-01-31
申请号：EP17187226.0
申请日：2012-05-08
发明人： Corkey, Britton Kenneth , Elzein, Elfatih , Jiang, Robert H , Kalla, Rao V , Kobayashi, Tetsuya , Koltun, Dmitry , Li, Xiaofen , Martinez, Ruben , Notte, Gregory , Parkhill, Eric Q , Perry, Thao , Zablocki, Jeff , Venkataramani, Chandrasekar , Graupe, Michael , Guerrero, Juan
IPC分类号： C07D237/32
摘要： The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I:
wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.摘要翻译： 本公开涉及作为钠通道抑制剂的化合物及其在治疗各种疾病状态（包括心血管疾病和糖尿病）中的用途。 在具体的实施方案中，所述化合物的结构由式I给出：其中Q，R 1，X 1，X 2，Y和R 2如本文所述，制备和使用所述化合物的方法和含有所述化合物的药物组合物。
-
-
-
搜索结果
4 条记录 (耗时 0.025 秒)
